Section Arrow
Quote
BPMC.NASDAQ
- Blueprint Medicines Corp
  suspend
Quotes are at least 15-min delayed:2025/07/20 16:59 EDT
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
129.46 
1-M High
129.65 
Volume 
-- 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
128 
Market Cap 
8.36B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 128.98 
20-SMA 128.6 
50-SMA 118.17 
52-W High 129.65 
52-W Low 73.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.51/0.62
Enterprise Value
8.77B
Balance Sheet
Book Value Per Share
5.30
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
249.38M
Operating Revenue Per Share
3.35
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 16:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patientsliving with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.